Publication Name	World Journal of Hypertension
Manuscript ID	14279
Country	United States

Received	2014-09-27 12:10
Peer-Review Started	2014-09-28 19:35
To Make the First Decision	2014-12-17 11:25
Return for Revision	2015-01-16 18:49
Revised	2015-02-19 00:00
Second Decision	2015-03-09 09:23
Accepted by Journal Editor-in-Chief	2015-03-09 18:19
Accepted by Executive Editor-in-Chief	2015-03-18 16:54
Articles in Press	2015-03-18 16:55
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-05-05 13:32
Publish the Manuscript Online	2015-05-21 14:33

ISSN	2220-3168 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Minireviews
Article Title	Symplicity-3 hypertension trial: Basic and clinical insights
Manuscript Source	Invited Manuscript
All Author List	Benjamin J Scherlag and Sunny S Po
Funding Agency and Grant Number
Corresponding Author	Benjamin J Scherlag, PhD, Heart Rhythm Institute, University of Oklahoma Health Sciences Center, 1200 Everett Drive (6E103), Oklahoma City, OK 73104, United States. benjamin-scherlag@ouhsc.edu
Key Words	Hypertension; Renal artery denervation; Aorticorenal ganglia; Atrial fibrillation
Core Tip	The failure of the Symplicity-3 trial which subjected patients to renal artery denervation to significantly reduce resistant hypertension has been ascribed to many factors. In this review, we focus on the lack of a “biomarker” as a major deficiency in achieving the expected efficacy. We also present experimental and clinical evidence to support the importance of a biomarker to acutely predict long term success of renal artery denervation for effective treatment for drug resistant hypertension.
Publish Date	2015-05-21 14:33
Citation	Scherlag BJ, Po SS. Symplicity-3 hypertension trial: Basic and clinical insights. World J Hypertens 2015; 5(2): 74-78
URL	http://www.wjgnet.com/2220-3168/full/v5/i2/74.htm
DOI	http://dx.doi.org/10.5494/wjh.v5.i2.74

Full Article (PDF)	WJH-5-74.pdf
Full Article (Word)	WJH-5-74.doc
Manuscript File	14279-Review.docx
Answering Reviewers	14279-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	14279-Conflict-of-interest statement.pdf
Copyright License Agreement	14279-Copyright assignment.pdf
Peer-review Report	14279-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	14279-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	14279-Scientific misconduct check.pdf
Scientific Editor Work List	14279-Scientific editor work list.pdf